# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-04-09T16:48:53.046616

---

**Idea Fidelity**

The paper pursues most elements of the original idea, but the execution diverges in important ways. The manifest proposed a monthly building-consent microdata analysis with a staggered difference-in-differences design (augmented with Callaway–Sant’Anna/Sun–Abraham accommodations), regional controls drawn from a rich set of data sources, and a complementary parcel-level RDD leveraging LINZ zoning and size thresholds. In contrast, the submitted paper aggregates to annual region-level data, treats MDRS adoption as a single simultaneous treatment across four regions, and relies solely on TWFE (with a simple Callaway–Sant’Anna robustness) to estimate the compositional effect. The paper also omits the promised parcel-level RDD, the detailed monthly time series, and the additional microdata sources (MBIE rental bonds, LINZ parcel/zoning) described in the manifest. These departures weaken the granularity and power of the identification strategy originally envisioned. In that sense, the paper captures the broad research question—whether MDRS shifted dwelling‐type composition—but misses key aspects of the identification strategy, data richness, and complementary empirical checks outlined in the manifest.

---

**Summary**

This paper studies New Zealand’s Medium Density Residential Standards (MDRS) reform by contrasting four treated regions (Waikato, Bay of Plenty, Wellington, Canterbury) against eleven never-treated controls in a difference-in-differences framework. Using region-level annual building consent data from 2016–2026, it finds a precise null effect on the multi-unit share of new construction and documents a suggestive negative effect on log multi-unit consents, arguing that constraints outside permitting—like costs, financing, and capacity—may explain the persistence of the “missing middle.”

---

**Essential Points**

1. **Granularity and Measurement of Treatment:** The current analysis aggregates to region-year observations even though MDRS applies to selected Tier 1 territorial authorities within those regions. This introduces substantial measurement error—treated regions contain non-MDRS TAs—and dilutes the treatment contrast. The original manifest proposed TA-month microdata, which would allow cleaner treatment assignment and finer temporal control for dynamics. Please either: (a) show that the region-level aggregation accurately proxies the MDRS treatment by demonstrating that treated TAs dominate the region and that the share of consents in treated TAs is sufficiently large, or (b) re-estimate using TA-month data (as originally planned) to avoid attenuation bias.

2. **Credibility of Control Group and Parallel Trends:** Tier 2 regions differ systematically from MDRS Tier 1 areas in population size, urbanization, and construction cycles. Without showing that the control group is plausibly on the same “trend” path absent treatment, the DiD estimate may capture broader structural differences. The event study (Table 3) is reassuring but only uses four pre-treatment years (2016–2021) and annual data. Please strengthen the parallel trends argument by (a) demonstrating the pre-trend visually and statistically using higher-frequency data (monthly/quarterly) if possible, (b) showing that observable characteristics (population, incomes, interest rates) evolved similarly before 2022, and (c) considering alternative control groups (e.g., synthetic controls combining multiple Tier 2 regions) or weighting schemes to better match the treated regions.

3. **Missing Identification Strategies Promised in Manifest:** The original idea promised additional empirical designs—the staggered DiD with monthly microdata and a parcel-level RDD around lot-size/zoning thresholds using LINZ data. These strategies would have addressed concerns about timing heterogeneity and compositional shifts at the parcel level. Their absence leaves the paper reliant on a single aggregated specification. If those designs remain infeasible, clearly explain why (data availability, complexity) and, ideally, replace with alternative strategies that approximate the original plan (e.g., use monthly Stats NZ releases to reconstruct higher-frequency trends, or leverage parcel-level zoning cutoffs that could still be matched to consent data). Without them, the identification rests on a single, potentially fragile model.

---

**Suggestions**

1. **Use Higher-Frequency Data:** The manifest emphasized monthly building consent microdata, which could vastly improve identification by (i) increasing the number of observations, (ii) allowing more precise treatment timing (since the first treated month is August 2022), and (iii) enabling inclusion of fixed effects for both TA and calendar month to absorb seasonality. Such data would also facilitate dynamic plots that convincingly show no pre-trend and that the null persists across different horizons. If the monthly series are accessible (Stats NZ publishes monthly releases), I strongly encourage re-estimating the DiD and event study at this frequency. Even if you stay with regions, monthly aggregation within regions would be an improvement.

2. **Clarify Treatment Definition and Timing:** The current specification treats “Post” as the years ended February 2023–2026, but MDRS became operative in August 2022, so the “year ended February 2023” contains only six treated months. The delayed-treatment robustness (Table 5 column 4) partly addresses this, but please be explicit about how partial treatment is handled. Consider defining treatment at the TA-month level (e.g., counting months from August 2022) or using a “fraction treated months” variable to avoid misclassifying the first post-treatment period. This matters for the event study and for interpreting the null effect.

3. **Address Attenuation from Mixed Region Populations:** Since regions mix MDRS cities with untreated TAs, the treatment indicator is “fuzzily” assigned. You could instrument the region-level treatment with the share of MDRS TAs (or consents) within the region if that share is available; alternatively, control for the proportion of consents arising in MDRS-affected TAs to absorb measurement error. Even simple sensitivity analyses—comparing the results in regions where MDRS TAs account for 90%+ of the region’s consents vs. those where they account for 50%—would help establish robustness.

4. **Explore Heterogeneous Effects with More Contextual Controls:** The manifest discussed threats like regional demand shocks. Augmenting the baseline by controlling for factors such as population growth, net migration, interest rates, and employment could make the comparison between treated and control regions more credible. Time-varying controls (especially those that capture demand and financing pressures) should be introduced carefully (ensuring they are pre-treatment or plausibly exogenous) but would help rule out confounding. For instance, if treated regions experienced larger COVID-era inflows, this could bias the share downward if housing preferences shifted differently.

5. **Extend Placebo and Mechanism Analysis:** The log multi-unit level result is interesting but only briefly discussed. Can you decompose this decline into (a) do multi-unit projects have longer approval times even after MDRS, and (b) do treated regions have a different mix of housing demand (e.g., fewer retirees)? Additionally, consider placebo outcomes beyond total consents—perhaps share of consents in apartments vs. townhouses, or share of multi-unit consents requiring resource consent (if available). These would help establish that MDRS specifically failed to alter the targeted compositional margin rather than being drowned out by other shocks.

6. **Revisit the RDD Opportunity:** The manifest suggested an RDD at lot-size thresholds, leveraging LINZ parcel data to examine whether MDRS led to more dwelling units on borderline lots. Even a simplified version of this—using zoning categories or parcel densities to compare lots just above/below the MDRS threshold—would add a valuable micro-level check. If you cannot merge parcel-level data due to data access issues, explain the constraint and consider alternative quasi-experimental variation (e.g., variation in the share of lots that already complied with MDRS before the reform).

7. **Discuss Power and Precision More Thoroughly:** The paper claims the null is “precise,” but readers will want to know the smallest effect that can be ruled out (e.g., a 95% confidence interval). While Table 2 partly does this, consider formalizing a minimum detectable effect (MDE) analysis or plotting the confidence interval relative to the pre-treatment variation. This will clarify whether the study is powered to detect economically meaningful compositional shifts.

8. **Enhance Discussion of External Validity:** The null finding is policy-relevant, but the discussion should acknowledge that the MDRS coincided with an unusual downturn—construction costs spiked, financing tightened, and migration patterns were volatile. You mention these channels, but consider comparing New Zealand’s experience to other upzoning cases (e.g., Minneapolis, Sao Paulo) in terms of macroeconomic timing. This will help readers assess whether the null is due to MDRS design or to the broader macro environment.

9. **Document Data Construction More Clearly:** Appendix A notes the data source, but it would be helpful to include a short table showing the share of consents by TA within each treated region (if possible) and to describe how “multi-unit” is defined (e.g., whether retirement villages are included). This transparency is especially important because aggregate data can mask heterogeneity.

10. **Ensure Robust Inference with Small Clusters:** With only 15 regions, clustered standard errors can be noisy. As a robustness check, report wild cluster bootstrap confidence intervals for the main coefficients. Additionally, since the Callaway–Sant’Anna estimator is already used, consider showing how sensitive the result is to the choice of estimation horizon or to the use of alternative estimators (e.g., stacked DiD or synthetic controls) to reassure readers about inference.

---

Overall, the paper addresses an important policy question and presents a clear null result, but it would benefit significantly from greater adherence to the fine-grained identification strategy described in the manifest. Improving the treatment measurement, strengthening the comparison group, and enriching the empirical approaches (monthly data, heterogeneity, RDD) would make the contribution much more compelling.
